Division of Cardiology, Santo Stefano Hospital, Via Suor Niccolina Infermiera, 20, Prato 59100, Italy.
Division of Cardiology, Santo Stefano Hospital, Via Suor Niccolina Infermiera, 20, Prato 59100, Italy.
Interv Cardiol Clin. 2020 Jul;9(3):369-383. doi: 10.1016/j.iccl.2020.02.006. Epub 2020 May 11.
Different pharmacologic agents have been tested in the effort to prevent contrast-induced acute kidney injury (AKI) in the last two decades. To date, however, no individual drug has received unanimous approval for this aim. Since 2014 statins have been included as preventive treatment in the European guidelines for revascularization procedures in cardiac patients. The present update presents the latest findings in this field focusing on the changing paradigms in the definition and consequently the approach to nephroprotection that considers clinical prognosis as the major issue. We note the current shift from attention to contrast-induced AKI to contrast-associated AKI.
在过去的二十年中，已经有不同的药物制剂被用于预防对比剂诱导的急性肾损伤（AKI）。然而，迄今为止，还没有一种药物制剂能获得一致的认可。自 2014 年以来，他汀类药物已被纳入欧洲心脏患者血运重建指南的预防治疗方案中。本更新版介绍了该领域的最新研究结果，重点关注定义方面的变化模式，以及由此产生的对肾脏保护的处理方法，将临床预后作为主要问题。我们注意到，目前的关注点已经从对比剂诱导的 AKI 转移到了对比剂相关的 AKI。
